mAb 253
An anti-SARS-CoV-2 monoclonal antibody.
General information
mAb 253 is a monoclonal antibody neutralizing SARS-CoV-2 (Supasa et al., 2021). It has been identified in a B cell of a COVID-19 convalescent patient (Dejnirattisai et al., 2021). mAb 253 neutralizes Delta and Omicron variants in vitro (possibly weaker compared to the wild-type strain). It is also active against other strains (Dejnirattisai et al., 2022; Liu et al., 2021; Supasa et al., 2021; Zhou et al., 2021).
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Spike protein ACE2 RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
sera from vaccinated or convalescent individuals; VeroE6/TMPRSS2 cells; SARS-CoV-2 (various strains) | 41.58 | Neutralizes Omicron variant in vitro. |
Jan/04/2022 |
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Spike protein Spike variant Crystallization Protein factor In vitro Mechanism Antibody |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients or vaccinated adults; Vero cells; SARS-CoV-2 (SARS-CoV-2/human/AUS/VIC01/2020 and SAR-CoV-2/B.1.1.7) | 41.58 | Neutralizes SARS-CoV-2 (including the Alpha variant) in vitro. |
Feb/18/2021 |
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Spike protein Cryo-EM Crystallization Novel compound Protein factor In vitro Mechanism Antibody |
in vitro biophysical assay; crystallization; cryo-EM; sera of COVID-19 convalescent patients; Vero cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (2019n-CoV/USA_WA1/2020 and SARS-CoV-2/human/AUS/VIC01/2020) | 41.58 | Neutralized SARS-CoV-2 in vitro. Its binding to RBD has been mapped. |
Feb/18/2021 |
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Spike protein RNA DNA Spike variant Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; plasma of COVID-19 (Beta strain) convalescent patients or vaccinated adults; Vero cells; SARS-CoV-2 (SARS-CoV-2/human/AUS/VIC01/2020 and SARS-CoV-2/B.1.351) | 41.58 | Although binding to the beta version of SARS-CoV-2 RBD is weaker compared to the wild type viral strain, the antibody neutralizes the virus in vitro. |
Feb/23/2021 |
Antibody evasion by the P.1 strain of SARS-CoV-2
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Gamma) | 41.58 | Neutralized all of the SARS-CoV-2 strains tested in vitro. |
Mar/30/2021 |
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; HEK293T/17-hACE2 cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Delta); (HIV-1) SARS-CoV-2 Spike-pseudotyped virus (various variants) | 41.58 | The antibody neutralized the Delta variant of SARS-CoV-2 in vitro. |
Jun/17/2021 |